The targeted RAS inhibitor therapy daraxonrasib demonstrated the potential to improve patient outcomes over current standard treatments for patients with RAS-mutant pancreatic cancer, according to ...

The 2026 NFL Draft is over, and now it's all about analyzing each pick and how they fit. The Washington Commanders selected six players in the 2026 draft, beginning with Ohio State linebacker Sonny ...

After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution Medicines is not resting on its laurels. The Bay Area biotech has spent several ...

After debunking earlier rumors that it was acquiring RAS superstar Revolution Medicines, AbbVie is now taking a more definitive step into the red-hot cancer field. The Chicago pharma has agreed to ...

Shares of Tejas Networks took a sharp dive on Tuesday morning, tumbling 10% at the open to touch ₹627.45, marking their lowest level in over two years. The slide followed a weak June quarter update ...